ASST Ospedale Maggiore di Crema
- Address
- Largo Ugo Dossena, 2, 26013 Crema, Italy
Digestive System Oncology
The ASST Ospedale Maggiore di Crema is conducting research focused on advanced HER2‑negative and PD‑L1 positive gastroesophageal adenocarcinoma, aiming to improve outcomes through a switch‑maintenance strategy that combines chemotherapy and immunotherapy.
- Evaluation of paclitaxel as part of maintenance therapy
- Role of ramucirumab in anti‑angiogenic treatment
- Use of tislelizumab to enhance immune response
- Impact of HER2‑negative status on therapeutic choices
- Significance of PD‑L1 positive biomarkers
Findings aim to extend progression‑free survival for patients with this digestive system cancer.
Melanoma Immunotherapy
In the field of skin cancer, the site is evaluating a novel antibody, ABP 206, against the established checkpoint inhibitor nivolumab for patients with unresectable or metastatic melanoma who have not received prior systemic therapy.
- Comparison of ABP 206 with standard immunotherapy
- Assessment of response in first‑line treatment setting
- Investigation of immune checkpoint inhibition mechanisms
- Monitoring of safety and tolerability profiles
- Exploration of biomarkers predictive of benefit
The study seeks to determine whether the new agent can provide a more effective treatment option for patients with advanced melanoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Fondazione GONO G.I.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ASST Ospedale Maggiore di Crema
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of ABP 206 Versus Nivolumab in Treatment-Naïve Patients with Unresectable or Metastatic Melanoma | Amgen Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 2 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.